This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Grogan TM, Van Camp B, Kyle RA, Muller-Hermelink HK, Harris NL . Plasma cell neoplasms. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds). Pathology and Genetics: Tumor of Haematopoietic and Lymphoid Tissues. WHO Classification of Tumors. IARC Press: Lyon, 2001, pp 142–156.
Hallek M, Leif Bergsagel P, Anderson KC . Multiple myeloma: increasing evidence for a multistep transformation process. Blood 1998; 91: 3–21.
Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999; 10: 105–115.
De Vos J, Jourdan M, Tarte K, Jasmin C, Klein B . JAK2 tyrosine kinase inhibitor tyrphostin AG490 downregulates the mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) pathways and induces apoptosis in myeloma cells. Br J Haematol 2000; 109: 823–828.
Lu X, Levine R, Tong W, Wernig G, Pikman Y, Zarnegar S et al. Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. Proc Natl Acad Sci USA 2005; 102: 18962–18967.
Baxter EJ, Scott LM, Campbell PJ, East C, Fourclas N, Swanton S et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054–1061.
Kralovics R, Passamonti F, Buser AS, Teo S, Tiedt R, Passweg JR et al. A gain -of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779–1790.
Levine RL, Loriaux M, Huntly BJ, Loh ML, Beram M, Stoffregen E et al. The JAK2 activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukaemia, but not in acute lymphoblastic leukaemia or chronic lymphocytic leukaemia. Blood 2005; 106: 3377–3379.
Fiorini A, Farina G, Reddiconto G, Palladino M, Rossi E, Za T et al. Screening of JAK2 V617F mutation in multiple myeloma. Leukemia 2006; 20: 1912–1913.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Huang, Q., Li, X., Chen, W. et al. Absence of JAK-2V617F point mutations in multiple myeloma. Leukemia 21, 813–814 (2007). https://doi.org/10.1038/sj.leu.2404551
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2404551